SEC Form 3 · accession 0001209191-18-052301
Urovant Sciences Ltd. · UROV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith Katkin
Officer — PEO;CEO-Urovant Sciences,Inc. · Director
Period of report
Sep 26, 2018
Accepted (ET)
Sep 26, 2018 · 4:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001740547
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.86 | holding | — | — | — | — | Sep 21, 2027 | Common Shares | 1,001,254 | — | D |
| Stock Option (Right to Buy)F2 | $4.01 | holding | — | — | — | — | Mar 18, 2028 | Common Shares | 24,630 | — | D |
Explanation of responses
- F125% of the total shares underlying the option shall vest and become exercisable on September 21, 2018; the remaining shares vest in 12 equal quarterly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date.
- F225% of the total shares underlying the option shall vest and become exercisable on March 14, 2019; the remaining shares vest in 12 equal quarterly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date.
Remarks
Exhibit List - Exhibit 24.1 - Power of Attorney